Ventyx Biosciences Reports Positive Phase 2 Data for Oral NLRP3 Inhibitor VTX3232 in Obesity and Cardiovascular Risk

Ventyx Biosciences Inc. (NASDAQ:VTYX) is one of the best NASDAQ stocks under $5 to buy now. On October 22, Ventyx Biosciences announced positive topline results from its Phase 2 study of the oral, once-daily drug VTX3232 in 175 participants with obesity and cardiovascular risk factors. The study was a randomized, double-blind, placebo-controlled, multicenter trial that evaluated VTX3232 versus placebo, alone or combined with semaglutide.

The primary goal was safety and tolerability, and the secondary endpoint was the effect on high-sensitivity C-reactive protein/hsCRP. VTX3232 was found to be safe and well-tolerated in all groups, with rates of adverse events comparable to placebo over the 12-week study period. Efficacy in Reducing InflammationVTX3232 monotherapy demonstrated significant reductions in inflammation.

The drug, which is an NLRP3 inhibitor, also reduced other key cardiovascular risk biomarkers. Ventyx Biosciences plans to provide future updates on the continued development of VTX3232, highlighting its potential to reduce the risk of cardiovascular events by targeting underlying inflammation.

Ventyx Biosciences Inc. (NASDAQ:VTYX) is a clinical-stage biopharmaceutical company that develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.